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Abstract 
Background  Atrial fibrillation (AF) and heart failure (HF) frequently co-occur in older individuals. Among patients with AF, HF in-
creases risks for stroke and death, but the associations between HF and incident cognition and physical impairment remain unknown. We aimed to 
examine the cross-sectional and prospective associations between HF, cognition, and frailty among older patients with AF. Methods  The 
SAGE-AF (Systematic Assessment of Geriatric Elements in AF) study enrolled 1244 patients with AF (mean age 76 years, 48% women) from 
five practices in Massachusetts and Georgia. HF at baseline was identified from electronic health records using ICD-9/10 codes. At baseline and 
1-year, frailty was assessed by Cardiovascular Health Survey score and cognition was assessed by the Montreal Cognitive Assessment. Results  
Patients with prevalent HF (n = 463, 37.2%) were older, less likely to be non-Hispanic white, had less education, and had greater cardiovascular 
comorbidity burden and higher CHA2DS2VASC and HAS-BLED scores than patients without HF (all P’s < 0.01). In multivariable adjusted re-
gression models, HF (present vs. absent) was associated with both prevalent frailty (adjusted odds ratio [aOR]: 2.38, 95% confidence interval [CI]: 
1.643.46) and incident frailty at 1 year (aOR: 2.48, 95% CI: 1.374.51). HF was also independently associated with baseline cognitive impair-
ment (aOR: 1.60, 95% CI: 1.222.11), but not with developing cognitive impairment at 1 year (aOR 1.04, 95%CI: 0.641.70). Conclusions  
Among ambulatory older patients with AF, the co-existence of HF identifies individuals with physical and cognitive impairments who are at 
higher short-term risk for becoming frail. Preventive strategies to this vulnerable subgroup merit consideration. 
J Geriatr Cardiol 2020; 17: 653658. doi:10.11909/j.issn.1671-5411.2020.11.007 
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1  Introduction 
Atrial fibrillation (AF) and heart failure (HF) are highly 
prevalent disorders in American adults that are associated 
with considerable morbidity and mortality, especially among 
older men and women.[1] These two conditions often co- 
exist and are associated with an increased risk of dying.  
The prevalence of AF increases significantly with ad-
vancing age.[2] Not surprisingly, individuals with AF are 
frequently affected by conditions common in older popula-
tions, particularly frailty[3] and cognitive decline.[4–6] Frailty 
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and cognitive impairment not only predict poor prognosis 
but also affect the treatment decisions among patients with 
AF. For example, clinicians frequently cite frailty as a rea-
son to withhold anticoagulation,[7,8] and cognitively im-
paired patients with AF are less likely to be offered ablation 
procedures.[9] Therefore, it is clinically important to identify 
patients with AF who are prone to become frail or cogni-
tively impaired and manage them proactively. AF often 
manifests with concomitant HF which has been associated 
with cognitive decline[10] and is intertwined with frailty.[11] 
However, among individuals with AF, it is unknown whe-
ther those with, as compared to those without HF, are more 
likely to decline in physical and cognitive wellness.  
Using data from the SAGE-AF study, which enrolled pa-
tients with AF  65-year-old and performed serial compre-
hensive geriatric examinations, we examined whether the 
presence of HF was associated with frailty and cognition 
impairment. We hypothesized that patients with AF and HF 
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are more prone to deterioration of frailty and cognitive 
function over time than individuals with AF only. 
2  Methods  
2.1  Study sample 
Details of the SAGE-AF study and the study inclusion 
and exclusion criteria have been previously described.[12] In 
brief, the inclusion criteria for SAGE-AF include: (1) have 
an ambulatory visit at one of four Central Massachusetts 
practices (University of Massachusetts Memorial Health 
Care Internal Medicine, Cardiology, or Electrophysiology, 
Heart Rhythm Associates of Central Massachusetts), one 
practice in Eastern Massachusetts (Boston University cardi-
ology), or two practices in Central Georgia (Family Health 
Center and Georgia Arrhythmia Consultants); (2) AF is 
present on an electrocardiogram or Holter monitor or if it is 
noted in any clinic note or hospital record); (3) be 65 years 
or older, and (4) have a CHA2DS2VASC
[13] risk score  2.  
A total of 1,244 participants completed their baseline 
examination. A follow-up visit was performed one year 
after the baseline. All participants provided informed writ-
ten consent. Study protocols were approved by the Univer-
sity of Massachusetts Medical School, Boston University, 
and Mercer University Institutional Review Boards. 
2.2  Data abstraction  
Trained study staff abstracted patient’s demographic and 
clinical characteristics from the medical record. Information 
abstracted included participants’ age, sex, race, insurance 
type, comorbidities relevant to stroke and bleeding risk (e.g., 
diabetes, hypertension, heart failure, anemia, chronic kidney 
disease), and cardiovascular treatments (i.e., use of anti- 
platelets). Relevant laboratory data, including serum creati-
nine, hemoglobin, and international normalized ratio values 
(over the past four weeks), were also abstracted.  
2.3  Assessment of HF, frailty, and cognition  
The presence of HF was abstracted from the medical re-
cords at the time of the baseline in-person study visit. Frailty 
was assessed by the Cardiovascular Health Survey frailty 
scale.[14] Its components include weight loss/shrinking, ex-
haustion, low physical activity, slow gait speed, and weak-
ness. Each component receives a point and the scale ranges 
from 0–5 (0: not frail, 1–2: pre-frail, 3 or more: frail). Cog-
nition was assessed by the Montreal Cognitive Assessment 
Battery,[15] a 30-item screening tool validated to detect mild 
cognitive impairment. Higher scores indicate better cogni-
tive function, with a score < 23 indicating cognitive im-
pairment.[16] Frailty and cognition were assessed at the base-
line and one-year follow-up visits.   
2.4  Statistical analysis 
The demographic and clinical characteristics of study 
participants were compared according to the presence of 
heart failure using analysis of variance for continuous vari-
ables and the Χ2 test for categorical variables. Logistic re-
gression was used to examine the relationship of heart fail-
ure to frailty and cognition, both at baseline and at one year. 
In examining the associations between heart failure and 
frailty, Model 1 was adjusted for age, sex, race, and educa-
tion; Model 2 was additionally adjusted for histories of dia-
betes, hypertension, stroke, lung disease and renal disease. 
For the association between heart failure and cognition, 
Model 1 was adjusted for age, sex, race, and education; 
Model 2 was additionally adjusted for hearing impairment, 
diabetes, hypertension, stroke, lung disease, and renal dis-
ease. Variables with potential to be confounders but not 
mediators of the associations of interest were selected into 
the models. Statistical analyses were performed using SAS 
9.4 (SAS Institute, Inc., Cary, NC). A two-sided P valve < 
0.05 was considered statistically significant. 
3  Results  
3.1  Study population 
Participants were on average 75.5  7.1 years old, 48.8% 
were women, and 84.9% were white. At baseline, 463 (37.2%) 
individuals had prevalent HF. Individuals with HF were 
older, less likely to be non-Hispanic white, had less education, 
and had greater cardiovascular comorbidity burden than 
individuals without HF. They had higher CHA2DS2VASC and 
HAS-BLED scores and these individuals were more likely 
to be taking a second antiplatelet agent and take warfarin 
than a direct oral anticoagulant (Table 1). At one year, 1097 
(88.2%) patients attended the follow up visit and 44 (3.5%) 
individuals had died. 
3.2 Heart failure and frailty  
At baseline, individuals with, as compared to those with-
out, HF were significantly more likely to be frail (23.5% 
versus 8.1%, P < 0.001). This association was attenuated 
slightly but remained significant after adjusting for several 
demographic, socioeconomic, psychological, and clinical 
characteristics (adjusted(a) odds ratio (OR): 2.15, 95% con-
fidence interval (CI): 1.40–3.33) (Table 2).  
Among individuals who were not frail at the baseline 
exam, those with HF were three-times more likely to have 
become frail at the 1-year follow up (12.5% vs. 2.9%). After  
WANG WJ, et al. HF, frailty and cognition in AF 655 
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Table 1.  Baseline characteristics by heart failure. 
 Heart failure  
Characteristic No (n = 781) Yes (n = 463) P-value 
Age 74.7 ± 6.9 76.9 ± 7.3 < 0.001 
6574 yrs 434 (55.6%) 192 (41.5%) 
7584 yrs 267 (34.2%) 187 (40.4%) 
85 yrs or older 80 (10.2%) 84 (18.1%) 
< 0.001 
Female 388 (49.7%) 219 (47.3%) 0.42 
Non-Hispanic White 692 (88.6%) 364 (78.6%) < 0.001 
Married 469 (60.1%) 225 (48.6%) < 0.001 
College graduate/Post graduate work 379 (49.3%) 148 (32.8%) < 0.001 
Income, $   
Less than 10,000 22 (3.4%) 30 (7.9%) 
10,000‒49,999 271 (41.3%) 201 (53.0%) 
50,000‒99,999 228 (34.7%) 101 (26.6%) 
>100,000 136 (20.7%) 47 (12.4%) 
< 0.001 
Commercial insurance 165 (21.1%) 60 (13.0%) < 0.001 
Social Isolation 94 (12.0%) 62 (13.4%) 0.49 
Depression 188 (24.1%) 165 (35.6%) < 0.001 
Anxiety 185 (23.7%) 106 (22.9%) 0.75 
CHA2DS2VASC score 3.8 ± 1.4 5.4 ± 1.4 < 0.001 
HAS-BLED score 3.1 ± 1.0 3.5 ± 1.1 < 0.001 
Smoking status   
Never smoker 382 (48.9%) 212 (45.8%) 
Former smoker 374 (47.9%) 241 (52.1%) 
Current smoker 25 (3.2%) 10 (2.2%) 
0.25 
Medical History    
Carotid disease 67 (8.6%) 66 (14.3%) < 0.001 
Coronary artery disease 163(20.9%) 185 (40.0%) < 0.001 
Peripheral vascular disease 85 (10.9%) 94 (20.3%) < 0.001 
Hypertension 690 (88.4%) 432 (93.3%) 0.005 
Diabetes 159 (20.4%) 187 (40.4%) < 0.001 
Hyperlipidemia 608 (77.9%) 388 (83.8%) 0.01 
Stroke 71 (9.1%) 51 (11.0%) 0.27 
Alcohol abuse/dependency 260 (33.3%) 124 (26.8%) 0.02 
Anemia 194 (24.8%) 197 (42.6%) < 0.001 
Asthma/COPD 147 (18.8%) 169 (36.5%) < 0.001 
Renal disease 157 (20.0%) 199 (43.0%) < 0.001 
Implantable cardiac device 173 (22.2%) 248 (53.6%) < 0.001 
Aspirin (current prescribed) 256 (32.8%) 186 (40.2%) 0.01 
Plavix (current) 30 (3.8%) 47 (10.2%) < 0.001 
Warfarin 347 (53.1%) 251 (61.1%) 0.01 
DOAC 307 (46.9%) 160 (38.9%) 0.01 
Data were presented as n (%) or mean ± SD. COPD: chronic obstructive pulmonary disease; DOAC: direct oral anticoagulant. 
 
adjusting for a variety of demographic, socioeconomic, psy-
chological, and clinical characteristics, this association re-
mained (aOR: 2.20, 95% CI: 1.114.33) (Table 3).  
3.3 Heart failure and cognition  
At baseline, individuals with HF were significantly more 
likely to be cognitively impaired (55.3% vs. 34.8%, P < 
0.001). After adjusting for age, sex, education, hearing im-
pairment, and a history of hypertension, stroke, lung disease, 
and renal disease as well socioeconomic and psycho-  
logical factors, this association remained significant (aOR: 
1.55, 95% CI: 1.14–2.11) (Table 4). 
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Table 2.  Association between prevalent heart failure and frailty at baseline. 
Odds ratio (95% CI) 
Heart failure Prevalent frailty 
 Unadjusted Model 1 Model 2 Model 3 
Yes (n = 463) 109 (23.5%) 3.51 (2.514.91) 2.93 (2.064.19) 2.38 (1.643.46) 2.15 (1.403.33) 
No (n = 781) 63 (8.1%) Reference 
Model 1 is adjusted for age, sex, race, and education; model 2 is additionally adjusted for diabetes, hypertension, stroke, lung disease, and renal disease; model 
3 is further adjusted for income, insurance, social isolation, alcohol abuse, depressive symptoms, and anxiety. 
Table 3.  Association between prevalent heart failure and incident frailty at year one. 
Odds ratio (95% CI) 
Heart failure Incident frailty
 Unadjusted Model 1 Model 2 Model 3 
Yes (n = 281) 35 (12.5%) 3.56 (2.086.12) 3.08 (1.745.44) 2.48 (1.374.51) 2.20 (1.114.33) 
No (n = 625) 24 (3.9%) Reference 
Model 1 is adjusted for age, sex, race, and education; model 2 is additionally adjusted for diabetes, hypertension, stroke, lung disease, and renal disease; model 
3 is further adjusted for income, insurance, social isolation, alcohol abuse, depressive symptoms, and anxiety. 
Table 4.  Association between prevalent heart failure and cognitive impairment at baseline. 
Odds ratio (95% CI) 
Heart failure 
Prevalent cognitive  
impairment Unadjusted Model 1 Model 2 Model 3 
HF (n = 463) 256 (55.3%) 2.31 (1.832.93) 1.67 (1.282.17) 1.60 (1.222.11) 1.55 (1.142.11) 
No HF (n =781) 272 (34.8%) Reference 
Model 1 is adjusted for age, sex, race, and education; model 2 is additionally adjusted for diabetes, hypertension, stroke, hearing impairment, lung disease, and 
renal disease; model 3 is further adjusted for income, insurance, social isolation, alcohol abuse, depressive symptoms, and anxiety. 
Table 5.  Association between prevalent heart failure and incident cognitive impairment at year one. 
Odds ratio (95% CI) 
Heart failure 
Incident cognitive  
impairment  Unadjusted Model 1 Model 2 Model 3 
Yes (n = 185) 35 (18.9%) 1.33 (0.852.08) 1.12 (0.711.79) 1.04 (0.641.70) 1.20 (0.702.08) 
No (n = 477) 71 (14.9%) Reference 
Model 1 is adjusted for age, sex, race, and education; model 2 is additionally adjusted for hearing impairment, diabetes, hypertension, stroke, hearing impair-
ment, lung disease, and renal disease; model 3 is further adjusted for income, insurance, social isolation, alcohol abuse, depressive symptoms, and anxiety. 
 
Among individuals who were not cognitively impaired at 
baseline, we examined the association between HF at base-
line and the development of cognitive impairment in one 
year. More individuals with HF developed cognitive im-
pairment in year than those without HF (18.9% vs. 14.9%) 
although the difference did not reach statistical significance 
(Table 5). 
4  Discussion  
In a contemporary cohort of older men and women with 
AF, we found that individuals with prevalent heart failure 
were more likely to be frail and cognitively impaired than 
individuals without. Furthermore, after one year follow up, 
prevalent heart failure was associated with incident frailty 
but not incident cognitive impairment.  
AF and HF are known to be intertwining conditions. In 
the Framingham Heart Study, half of individuals with HF 
had AF and one third of individuals with AF had HF. Also, 
the presence of one condition begets the other. Furthermore, 
the concurrence of AF and HF portended worse mortality 
than the presence of AF alone.[6] Adding to the prior litera-
tures, our study was the first to evaluate the incident physi-
cal and cognitive function by HF status among individuals 
with AF and demonstrated that individuals with co-occurr-
ing HF had higher risk of physical and cognitive impairment 
than those with AF alone. As shown in our data, older indi-
viduals with HF and AF often have more medical problems 
than those with AF alone, which may explain the associa-
tion between HF and frailty among older individuals with 
AF. As frailty is predictive of mortality and poor quality of 
life in individuals with AF,[17,18] our finding highlighted that 
the presence of HF identifies a high-risk group with worse 
clinical outcomes among older patients with AF.  
Individuals with coexisting HF and AF frequently require 
comprehensive management,[19] including guideline directed 
WANG WJ, et al. HF, frailty and cognition in AF 657 
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medical therapy for HF, anticoagulation for stroke preven-
tion, and catheter ablation to maintain sinus rhythm as it has 
been recently shown to reduce mortality and HF hospitali-
zation in this population.[20] There is growing evidence that 
being frail may preclude patients from benefiting some of 
these therapies. For example, physicians may withhold an-
ticoagulation in frail patients citing concerns of fall and 
bleeding.[21] Recently, being frail was associated with higher 
mortality and more rehospitalization after atrial fibrillation 
ablation.[22] Also, physicians are often hesitant to offer inva-
sive procedures to frail patients. As we showed that 10% of 
non-frail individuals with HF and AF became frail in one 
year of follow-up, there is an urgency to manage these indi-
viduals proactively and aggressively before they become 
frail. Whether interventions can prevent or delay the devel-
opment of frailty in this population requires further studies.  
HF and AF have both been individually associated with 
cognitive impairment.[5,10] This is in line with the observed 
additively negative effect of both conditions on cognition: 
more than half of participants with HF and AF were cogni-
tive impaired and they were 2 times more likely to be cogni-
tive impaired than those with AF alone. We have recently 
shown that vision and hearing impairment are prevalent in 
this population.[23] Taken together, the combination of HF, 
cognitive impairment, and sensory impairment will most 
likely create communication barriers between patients and 
caregivers. It obstructs patients’ understanding of the dis-
ease and participation of the care and results in management 
difficulties and poorer clinical outcomes. Further studies are 
necessary to test whether interventions can improve patient 
communication and clinical outcomes in this vulnerable 
population. Unlike previous studies,[10] we did not observe 
difference in incident cognitive impairment by HF status, 
which may be due to the shorter follow up duration.  
Our study has several strengths. First, we assessed cogni-
tion and frailty prospectively with validated instruments. 
Also, the study population is geographically diverse, and 
participants have a high prevalence of comorbidities which 
emulates real-world practice. Several limitations should be 
mentioned. First, the follow up to date was 1-year and could 
be short to evaluate change in cognitive function. Second, 
only 20% of individuals had information regarding the left 
ventricular ejection fraction (LVEF) (n = 260, 63 with re-
duced EF and 197 with preserved EF). The type of heart 
failure was not statistically associated with either cognition 
or frailty. Because of the limited data on LVEF, the finding 
was not conclusive. However, the lack of modification by 
type of heart failure and cognitive decline was consistent 
with prior findings from the Cardiovascular Health Study.[10] 
Also, it would be ideal to know how many individuals de-
veloped and recovered from heart failure during the follow 
up. However, we did not have information on how many 
individuals developed incident heart failure during the one 
year follow up. Further studies on how change in heart fail-
ure status affects physical and cognitive function in indi-
viduals with AF are needed. The type of AF (paroxysmal or 
permeant) was not available. Lastly, residual confounding is 
always possible as it is an observational study. 
In conclusion, among older patients with AF, the co-ex-
istence of HF identifies a subgroup with more physical and 
cognitive impairments who are also at higher short-term risk 
for becoming frail. Preventive strategies to this vulnerable 
subgroup merits consideration to slow the acceleration of 
functional decline.   
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